Back to Search
Start Over
Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
- Source :
-
International Journal of Cardiology . Apr2019, Vol. 281, p179-185. 7p. - Publication Year :
- 2019
-
Abstract
- Abstract Despite significant advances in the last 30 years in reducing morbidity and mortality from heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based therapies, patients remain at a high risk of adverse cardiovascular outcomes. Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitors (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and improve symptoms in patients with chronic, ambulatory, symptomatic HFrEF in a large, phase 3, multicentre, international, randomised controlled trial, PARADIGM-HF, when compared to the gold-standard angiotensin converting enzyme inhibitor, enalapril. This article will review the development of sacubitril/valsartan, the evidence for its use and its current and future role in the management of HFrEF. Highlights • Natriuretic peptides have protective properties in heart failure with reduced ejection fraction. • Neprilysin degrades natriuretic peptides as well as other vasoactive peptides. • Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor. • Sacubitril/valsartan reduces mortality, the risk of heart failure hospitalisation and symptoms in patients with heart failure compared with the ACE-inhibitor, enalapril. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ACE inhibitors
*HEART failure
*NATRIURETIC peptides
*ANGIOTENSINS
Subjects
Details
- Language :
- English
- ISSN :
- 01675273
- Volume :
- 281
- Database :
- Academic Search Index
- Journal :
- International Journal of Cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 134883032
- Full Text :
- https://doi.org/10.1016/j.ijcard.2018.05.124